• News
  • SAN DIEGO
  • Health

Two labs sign with Critical Diagnostics

San Diego-based Critical Diagnostics announced Thursday an agreement with Quest Diagnostics (NYSE: DGX) and Berkeley HeartLab under which both Quest and Berkeley will offer ST2 testing services based on Critical Diagnostics’ Presage ST2 Assay.

Also announced was Critical Diagnostics' separate agreement with Laboratory Corporation of America (NYSE: LH), better known as LabCorp, to offer testing of the Presage ST2 Assay.

Critical Diagnostics, a biomarker company focused on cardiovascular diseases, combines with LabCorp to perform some 1.5 million tests per day, according to a release from Critical Diagnostics.

The Presage ST2 Assay is an FDA-approved assessment for the prognosis of patients diagnosed with chronic heart failure.

Unlike many other cardiac biomarkers, ST2 levels change quickly in response to changes in the patient’s condition — thus helping physicians make informed decisions on an appropriate course of action to take. The American Heart Association reports that heart failure affects around 6 million Americans per year, with roughly 600,000 new diagnoses annually.

Clinical studies have demonstrated that high levels of soluble ST2 are predictive of adverse patient outcomes and death.

“We are extremely proud to be associated with these two exceptional organizations,” said James Snider, president of Critical Diagnostics. “The Quest/Berkeley HeartLab and LabCorp collaborations, in addition to our existing clinical lab relationships, mean that physicians nationwide will now have access to Presage ST2 testing to help guide and improve heart failure patient outcomes.”

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.